Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0X2DK
|
||||
| Former ID |
DAP000478
|
||||
| Drug Name |
Phenoxybenzamine
|
||||
| Synonyms |
Bensylyt; Bensylyte; Benzylyt; Dibenylene; Dibenylin; Dibenyline; Dibenziran; Dibenzylene; Dibenzylin; Dibenzyran; Fenossibenzamina; Fenoxibenzamina; Phenoxybenzaminum; Bensylyt NEN; Fenossibenzamina [DCIT]; POB HCl; Phenoxybenzamine Hcl; A 688; Dibenzyline (TN); Fenoxibenzamina [INN-Spanish]; Phenoxybenzamine (INN);Phenoxybenzamine [INN:BAN]; Phenoxybenzaminum [INN-Latin]; N-Phenoxyisopropyl-N-benzyl-beta-chloroethylamine; Benzyl(2-chloroethyl)-(1-methyl-2-phenoxyethyl)amine; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzenemethanamine; N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine; N-benzyl-N-(2-chloroethyl)-1-phenoxypropan-2-amine; N-(2-chloroethyl)-N-(phenylmethyl)-1-(phenyloxy)propan-2-amine; 2-(N-Benzyl-2-chloroethylamino)-1-phenoxypropane; 688A
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Malignant phaeochromocytoma; Benign prostatic hypertrophy; Malignant essential hypertension [ICD10:N40, C61] | Approved | [1] | ||
| Therapeutic Class |
Antihypertensive Agents
|
||||
| Company |
Concordia Pharmaceuticals Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H22ClNO
|
||||
| InChI |
InChI=1S/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3
|
||||
| InChIKey |
QZVCTJOXCFMACW-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 59-96-1
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9639, 4448492, 7980292, 8152929, 10529050, 11121824, 11122304, 11335975, 11361214, 11363032, 11363272, 11365594, 11365834, 11368156, 11368396, 11371195, 11371196, 11373757, 11374297, 11376318, 11376558, 11462186, 11466972, 11468092, 11485565, 11486803, 11489631, 11492584, 11494192, 14873959, 26752309, 26752310, 29223852, 46507191, 47291177, 47365231, 47515348, 47662322, 47810788, 47885450, 48185031, 48185032, 48259269, 48334533, 48416417, 49698954, 49893224, 50105233, 50105234, 50319296
|
||||
| SuperDrug ATC ID |
C04AX02
|
||||
| SuperDrug CAS ID |
cas=000059961
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Catecholamine-secreting neuroblastoma in a 4-month-old infant: perioperative management. J Clin Anesth. 2009 Feb;21(1):54-6. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.